|
|
DU 145
|
|
|
KR Stone |
|
Biosafety Level: |
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent |
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: prostate Disease: carcinoma Derived from metastatic site: brain |
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
transfection host (Nucleofection technology from Lonza Roche FuGENE® Transfection Reagents) |
|
|
Yes
|
|
|
Blood Type O; Rh+ |
|
|
D7S820: 7, 10, 11 D13S317: 12, 13, 14 D5S818: 10, 13 vWA: 17, 18, 19 THO1: 7 CSF1PO: 10, 11 TPOX: 11 D16S539: 11, 13 Amelogenin: X, Y |
|
|
This is a hypotriploid human cell line. Both 61 and 62 chromosome numbers had the highest rate of occurrence in 30 metaphase counts.The rate of higher ploidies was 3%. The t(11q12q), del(11)(q23), 16q+, del(9)(p11), del(1)(p32) and 6 other marker chromosomes were found in most cells. The N13 was usually absent. The Y chromosome is abnormal through translocation to an unidentified chromosomal segment. The X chromosome was present in single copy. |
|
|
AK-1, 1 ES-D, 1 G6PD, B GLO-I, 2 Me-2, 1-2 PGM1, 1 PGM3, 2 |
|
|
69 years |
|
|
male |
|
|
Caucasian |
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
|
|
Protocol: - Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
- Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended Medium Renewal: 2 to 3 times per week |
|
|
Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liqid nitrogen vapor temperature |
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003 recommended serum:ATCC 30-2020 purified DNA:ATCC HTB-81D 0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101 Cell culture tested DMSO:ATCC 4-X |
|
|
22289: Papsidero LD, et al. Prostate antigen: a marker for human prostate epithelial cells. J. Natl. Cancer Inst. 66: 37-42, 1981. PubMed: 6935463 22858: Stone KR, et al. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 21: 274-281, 1978. PubMed: 631930 23028: Mickey DD, et al. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res. 37: 4049-4058, 1977. PubMed: 908039 23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212 32283: Hu SX, et al. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res. 57: 3339-3343, 1997. PubMed: 9269991 32341: Sheng S, et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA 93: 11669-11674, 1996. PubMed: 8876194 32460: Carter RE, et al. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA 93: 749-753, 1996. PubMed: 8570628 32486: Nupponen NN, et al. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet. Cytogenet. 101: 53-57, 1998. PubMed: 9460501 32768: Robinson D, et al. A tyrosine kinase profile of prostate carcinoma. Proc. Natl. Acad. Sci. USA 93: 5958-5962, 1996. PubMed: 8650201 32916: Su ZZ, et al. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc. Natl. Acad. Sci. USA 93: 7252-7257, 1996. PubMed: 8692978 32925: Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224 33090: Boffa LC, et al. Invasion of the CAG triplet repeats by a complementary peptide nucleic acid inhibits transcription of the androgen receptor and TATA-binding protein genes and correlates with refolding of an active nucleosome containing a unique AR gene sequence. J. Biol. Chem. 271: 13228-13233, 1996. PubMed: 8662737 |
|
|